Asoxime dichloride (HI-6) is an antagonist to acetylcholine receptors (AChRs) including the nicotinic receptor, α7 nAChR. Asoxime dichloride involves in modulating immunity response. Asoxime dichloride (HI-6) can be used as an antigen and improves vaccination efficacy in the nervous system^[1]. IC50 & Target: IC50: acetylcholine receptors (AChRs)^[1] In Vivo: Asoxime dichloride (intramuscular injection into the rear limb; 2% and 0.2% of median lethal dose 15.6 and 1.56 mg/kg; 21 or 65 days) significantly improved vaccination efficacy as a dose-dependent manner when KLH is 1 mg/kg. A combination of HI-6 and keyhole limpet hemocyanin (KLH) produces a vaccination of almost the same efficacy as that for Freund's complete adjuvant^[1].